Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-021: sacituzumab tirumotecan maintenance ± bevacizumab vs standard of care in non-HRD ovarian cancer
jRCT2031250647Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing sacituzumab tirumotecan maintenance ± bevacizumab with standard-of-care (bevacizumab maintenance or observation) (2 arms). Primary endpoint: Progression-free survival (PFS) per RECIST 1.1. Started Mar 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2031250647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250647.